News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
367,975 Results
Type
Article (21013)
Company Profile (127)
Press Release (346835)
Section
Business (118283)
Career Advice (978)
Deals (20749)
Drug Delivery (84)
Drug Development (57689)
Employer Resources (85)
FDA (8912)
Job Trends (8729)
News (207968)
Policy (18673)
Tag
Academia (953)
Africa (424)
Alliances (29270)
Alzheimer's disease (661)
Antibody-drug conjugate (ADC) (41)
Approvals (8885)
Arizona (48)
Artificial intelligence (53)
Asia (26565)
Australia (3425)
Bankruptcy (178)
Best Places to Work (6271)
Biosimilars (57)
Biotechnology (59)
C2C Services and Suppliers (18444)
California (954)
Canada (567)
Cancer (238)
Career advice (789)
Cell therapy (55)
China (81)
Clinical research (46505)
Collaboration (78)
Connecticut (36)
COVID-19 (1223)
Cystic fibrosis (45)
Data (134)
Diabetes (53)
Diagnostics (2203)
Drug pricing (74)
Earnings (47179)
Employer resources (76)
Europe (55177)
Events (54649)
Executive appointments (79)
FDA (9014)
Florida (118)
Funding (52)
Gene therapy (63)
GLP-1 (443)
Government (1995)
Healthcare (7701)
Hotbed/Location (251272)
Illinois (103)
Indiana (84)
Infectious disease (1240)
Inflammatory bowel disease (60)
Interviews (143)
IPO (8794)
Job creations (2520)
Job search strategy (724)
Kansas (54)
Layoffs (263)
Legal (4208)
Liver cancer (32)
Lung cancer (60)
Manufacturing (63)
Maryland (162)
Massachusetts (830)
Medical device (3417)
Medtech (3418)
Mergers & acquisitions (11866)
Metabolic disorders (211)
Minnesota (72)
Neuroscience (753)
New Jersey (354)
New York (314)
NextGen Class of 2024 (2772)
Non-profit (1330)
North Carolina (334)
Northern California (448)
Obesity (137)
Ohio (53)
Opinion (167)
Patents (53)
Pennsylvania (289)
People (34136)
Pharmaceutical (62)
Phase I (14314)
Phase II (20075)
Phase III (15851)
Pipeline (91)
Podcasts (47)
Policy (51)
Postmarket research (1772)
Preclinical (5169)
Press Release (35)
Rare diseases (81)
Real estate (3326)
Regulatory (12987)
Research institute (1076)
Resumes & cover letters (166)
South America (638)
Southern California (403)
Startups (2126)
Texas (107)
United States (4222)
Vaccines (217)
Washington State (112)
Weight loss (134)
Date
Today (3)
Last 7 days (340)
Last 30 days (1182)
Last 365 days (22759)
2024 (15326)
2023 (23912)
2022 (30832)
2021 (31824)
2020 (29230)
2019 (23718)
2018 (18113)
2017 (19600)
2016 (18160)
2015 (21142)
2014 (16345)
2013 (13561)
2012 (14540)
2011 (14951)
2010 (13736)
367,975 Results for "4d pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
4D Molecular Therapeutics today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug Application (IND) for 4D-175, an R100 vector-based intravitreal genetic medicine, for the treatment of patients with GA.
June 24, 2024
·
7 min read
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here,
BioSpace
examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
·
5 min read
·
Mollie Barnes
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Genetown
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
Inozyme Pharma, Inc today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.
May 8, 2024
·
1 min read
Approvals
ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions
ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.
August 12, 2024
·
2 min read
·
Tristan Manalac
FDA
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
June 26, 2024
·
10 min read
Press Releases
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
August 27, 2024
·
8 min read
Business
FSD Pharma provides Corporate Update
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.
June 28, 2024
·
10 min read
Genetown
4D Path Announces New Data Highlighting Efficacy of the Q-Plasia OncoReader (QPOR™) Platform
4D Path is pleased to announce today new clinical data highlighted in two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, 2024 at McCormick Place, Chicago.
May 30, 2024
·
4 min read
Drug Development
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
4D Molecular Therapeutics announced that interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 47th European Cystic Fibrosis Conference, taking place in Glasgow, UK.
May 30, 2024
·
6 min read
1 of 36,798
Next
